X4 Pharmaceuticals Information

We are a late-stage clinical biopharmaceutical company driven to improve the lives of people with rare diseases of the immune system and few to no treatment options. Our lead clinical candidate is mavorixafor, a selective, small-molecule antagonist of chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. Due to its demonstrated ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream, we believe that mavorixafor has the potential to provide therapeutic benefit across a variety of chronic neutropenic disorders, including WHIM syndrome, a rare, primary immunodeficiency. Following successful completion of a global, pivotal, Phase 3 clinical trial, we are seeking U.S. regulatory approval of oral, once-daily mavorixafor for the treatment of people aged 12 years and older with WHIM syndrome. We are also currently planning a Phase 3 clinical program evaluating mavorixafor in certain chronic neutropenic disorders. X4 is a public biopharmaceutical company (Nasdaq: XFOR) headquartered in Boston, Massachusetts, with a research center of excellence in Vienna, Austria.